PD

Peter Dudek

President & Managing Partner, MRL Ventures Fund at Merck

Cambridge, Massachusetts

Investor
VC

Invests in

Stages:

Series A
Seed

  • Min Investment:

    $15,000,000.00

  • Max Investment:

    $20,000,000.00

  • Target Investment:

    $17,500,000.00

Skills

Biotechnology
Biopharmaceuticals
Medical Devices
Life Sciences
Diagnostics
Healthcare
Venture Capital
Entrepreneurship
Valuation
Competitive Intelligence
Market Analysis
Due Diligence
Lifesciences
Molecular Biology
Molecular Cloning
Biochemistry
Genetics
Commercialization
Data Analysis
Neuroscience

Education

Investments

Carisma Therapeutics

Series B

Total Funding: $150M

Mozart Therapeutics

Series A

Total Funding: $55M

Xilio Therapeutics

Series B

Total Funding: $330M

Work Experience

Insamo

2024

  • Board Observer

    2024

Merck

2018

  • President & Managing Partner, MRL Ventures Fund

    2021

  • Partner, MRL Ventures Fund

    2018 - 2021

InduPro

2022

  • Board Director

    2022

Photys Therapeutics

2021

  • Board Observer

    2021

Tallac Therapeutics

2021

  • Board Director

    2021

Mozart Therapeutics, Inc

2020

  • Board Director

    2020

Ambagon Therapeutics

2020

  • Board Director

    2020

Caraway Therapeutics, Inc.

2021 - 2023

  • Board Director

    2021 - 2023

    Acquired by Merck.

Carisma Therapeutics

2018 - 2023

  • Board Observer

    2018 - 2023

LifeMine Therapeutics

2021 - 2023

  • Board Observer

    2021 - 2023